Shasun Pharmaceuticals has received its board’s approval for the preferential allotment to Caduceus Mauritius Asia (CAML), a wholly owned subsidiary of OrbiMed Asia Partners. The company will allot 65,78,947 equity shares at Rs 76 per share, aggregating to Rs 50 crore.
OrbiMed is the world’s largest healthcare dedicated investment firm, with about $5 billion in assets under management.
Shasun Pharmaceuticals manufactures active pharmaceutical ingredients (APIs), their intermediates and enteric coating excipients with a significant presence in some key generics. Shasun has created a strong product portfolio, building on its R & D Expertise, regulatory capabilities and multi scale production capacities. It is one of the largest producers of Ibuprofen worldwide.
